Breakthrough trial aims to extend lives of pancreatic cancer patients
NCT ID NCT07490301
Summary
This study is testing whether adding an experimental drug called telisotuzumab adizutecan to standard chemotherapy works better for people with advanced pancreatic cancer that has spread. About 900 patients worldwide will receive either the new combination or standard treatment alone. Researchers will measure how well the cancer responds and whether patients live longer with the new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.